Elevated estradiol with prolonged mifepristone to treat progesterone-receptor positive meningioma

Devora Aharon, O. Carpinello, L. Bishop, A. DeCherney
{"title":"Elevated estradiol with prolonged mifepristone to treat progesterone-receptor positive meningioma","authors":"Devora Aharon, O. Carpinello, L. Bishop, A. DeCherney","doi":"10.1097/GRH.0000000000000019","DOIUrl":null,"url":null,"abstract":"Objective: To report a finding of persistently elevated estradiol (E2) after prolonged mifepristone use for treatment of progesterone-receptor positive meningioma, an association which has not previously been reported. Design: This is a case report. Setting: Outpatient Reproductive Endocrine clinic at a tertiary referral center. Case Report: A 48-year-old gravida 1 para 0-0-1-0 with progesterone-receptor positive meningioma, recurrent after multiple debulking surgeries. Patient was treated with mifepristone for 11 years with symptomatic improvement and tumor shrinkage. Levels of follicle-stimulating hormone, luteinizing hormone, and estradiol (E2) were followed throughout the patient’s course of mifepristone therapy. E2 levels were found to be persistently elevated to 500–700 pg/mL. Materials and Methods: Enhanced E2 assay, a liquid-chromatography tandem mass spectrometry (LC-MS/MS) based assay, was measured simultaneously with the routinely used immunoassay for 5 years in attempt to obtain a more accurate assessment. Results: E2 levels using the standard immunoassay were found to be persistently elevated while the patient was taking mifepristone. Using the enhanced LC-MS/MS assay, E2 was initially elevated, however was subsequently low. After the patient discontinued the medication, E2 levels as measured by the immunoassay normalized. Conclusions: Prolonged mifepristone use was found to be associated with markedly elevated E2 levels in our patient. If this is a true elevation, it may help explain the incidence of endometrial hyperplasia and endometrial polyps with prolonged mifepristone use. However, this was likely a false elevation, potentially due to cross-reactivity of mifepristone with the immunoassay, given the normal values obtained with the enhanced LC-MS/MS E2 assay. Whether prolonged mifepristone use may cause true or falsely elevated E2 in a wider population, and the mechanism through which it does so, should be further investigated.","PeriodicalId":92638,"journal":{"name":"Global reproductive health","volume":"3 1","pages":"e19"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global reproductive health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/GRH.0000000000000019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Objective: To report a finding of persistently elevated estradiol (E2) after prolonged mifepristone use for treatment of progesterone-receptor positive meningioma, an association which has not previously been reported. Design: This is a case report. Setting: Outpatient Reproductive Endocrine clinic at a tertiary referral center. Case Report: A 48-year-old gravida 1 para 0-0-1-0 with progesterone-receptor positive meningioma, recurrent after multiple debulking surgeries. Patient was treated with mifepristone for 11 years with symptomatic improvement and tumor shrinkage. Levels of follicle-stimulating hormone, luteinizing hormone, and estradiol (E2) were followed throughout the patient’s course of mifepristone therapy. E2 levels were found to be persistently elevated to 500–700 pg/mL. Materials and Methods: Enhanced E2 assay, a liquid-chromatography tandem mass spectrometry (LC-MS/MS) based assay, was measured simultaneously with the routinely used immunoassay for 5 years in attempt to obtain a more accurate assessment. Results: E2 levels using the standard immunoassay were found to be persistently elevated while the patient was taking mifepristone. Using the enhanced LC-MS/MS assay, E2 was initially elevated, however was subsequently low. After the patient discontinued the medication, E2 levels as measured by the immunoassay normalized. Conclusions: Prolonged mifepristone use was found to be associated with markedly elevated E2 levels in our patient. If this is a true elevation, it may help explain the incidence of endometrial hyperplasia and endometrial polyps with prolonged mifepristone use. However, this was likely a false elevation, potentially due to cross-reactivity of mifepristone with the immunoassay, given the normal values obtained with the enhanced LC-MS/MS E2 assay. Whether prolonged mifepristone use may cause true or falsely elevated E2 in a wider population, and the mechanism through which it does so, should be further investigated.
升高雌二醇联合延长米非司酮治疗孕激素受体阳性脑膜瘤
目的:报告长期使用米非司酮治疗孕激素受体阳性脑膜瘤后雌二醇(E2)持续升高的发现,这种相关性以前从未报道过。设计:这是一份案例报告。设置:三级转诊中心的生殖内分泌门诊。病例报告:一名48岁的孕妇,1段0-0-1-0,患有孕激素受体阳性脑膜瘤,在多次拆封手术后复发。患者应用米非司酮治疗11年,症状得到改善,肿瘤缩小。在患者米非司酮治疗的整个过程中,跟踪卵泡刺激素、黄体生成素和雌二醇(E2)的水平。E2水平持续升高至500–700 pg/mL。材料和方法:增强型E2测定法是一种基于液相色谱-串联质谱法(LC-MS/MS)的测定法,与常规使用的免疫测定法同时测量5年,试图获得更准确的评估。结果:在患者服用米非司酮期间,使用标准免疫测定法发现E2水平持续升高。使用增强型LC-MS/MS测定法,E2最初升高,但随后降低。患者停药后,通过免疫测定测定的E2水平正常化。结论:我们发现长期使用米非司酮与患者E2水平显著升高有关。如果这是一个真正的升高,它可能有助于解释长期使用米非司酮后子宫内膜增生和子宫内膜息肉的发生率。然而,这可能是一种错误的升高,可能是由于米非司酮与免疫测定的交叉反应,考虑到增强型LC-MS/MS E2测定获得的正常值。在更广泛的人群中,长期使用米非司酮是否会导致E2的真实或虚假升高,以及其作用机制,还需要进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信